Last reviewed · How we verify

mohamed bouchoucha — Portfolio Competitive Intelligence Brief

mohamed bouchoucha pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
placebo based quadriple therapy placebo based quadriple therapy marketed
metronidazole based quadriple therapy metronidazole based quadriple therapy marketed Antibiotic combination therapy Helicobacter pylori DNA and bacterial cell integrity Gastroenterology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Mackay Memorial Hospital · 1 shared drug class
  2. Takeda · 1 shared drug class
  3. University of Valencia · 1 shared drug class
  4. West Virginia University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for mohamed bouchoucha:

Cite this brief

Drug Landscape (2026). mohamed bouchoucha — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mohamed-bouchoucha. Accessed 2026-05-16.

Related